Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a ...

Ginkgo Bioworks Holdings, Inc. (DNA) has been on a downward spiral lately with significant selling pressure. After declining ...

Ginkgo Bioworks gains a $29 million contract by ARPA-H to develop distributed manufacturing of essential medicines using wheat germ cell-free expression systems.

We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where ...

Part of the partners' plan is to use Plex's AI to identify potential new uses for existing treatments that can be used to ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Plex Research is partnering with Ginkgo Bioworks to use AI to deepen understanding of the mechanisms of action of existing ...

Ginkgo Bioworks (DNA) is down -4.8%, or -27c to $5.39.Don't Miss Our End of Quarter Offers: Discover the latest stocks recommended by top Wall ...

Charles Schwab Investment Management Inc. increased its position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Free Report) ...

Latest data shows the largest indicative borrow rate increases among liquid option names include: Humacyte (HUMA) 20.80% +5.81, Ginkgo Bioworks ...

The conference runs from April 2-4, 2025. Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations ...